Skip to content

US · BBNX · MEDICAL - DEVICES

Beta Bionics, Inc. (BBNX) intrinsic value and stock valuation

$13.36as of 2026-11-21 · Mkt cap 625.81M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Beta Bionics, Inc. DCF and intrinsic value

InvestorsCraft values BBNX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from BBNX’s statements →

Beta Bionics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Irvine, CA 92618 betabionics.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$100.3M
20222025
Net income
-$-73.2M
20222025
Free cash flow
-$-56.22M
20222025
Total equity
$287.6M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$100.3M$65.1M$12M$180K
Operating income-$-71.68M-$-45.25M-$-35.85M-$-65.84M
Net income-$-73.2M-$-54.76M-$-44.1M-$-64.75M
EPSd-$-1.81M-$-1.28M-$-1.03M-$-1.51M
Operating cash flow-$-50.92M-$-48.27M-$-32.45M-$-60.21M
Capital expenditure-$-5.3M-$-3.4M-$-400K-$-770K
Free cash flow-$-56.22M-$-51.67M-$-32.85M-$-60.98M
Total assets$328.7M$149.7M$110M$35.5M
Total debt$7.3M$7.25M$4.22M$4.13M
Net debt-$-24.27M-$-23.18M-$-22.34M-$-23.54M
Total equity$287.6M$76M$58.6M-$-170.03M
Cash and short-term investments$219.1M$103.6M$96.8M$27.7M
Income statement
2025202420232022
Revenue$100.3M$65.1M$12M$180K
Cost of revenue$44.7M$29.2M$5.69M$0.00
Gross profit$55.5M$35.9M$6.31M$180K
Research and development expenses$34.8M$26.2M$17.9M$31.4M
Selling, general and administrative expenses$92.4M$55M$24.2M$33.5M
Other expenses$0.00$0.00$0.00$1.1M
Operating expenses$127.2M$81.1M$42.2M$66M
Cost and expenses$171.9M$110.4M$47.8M$66M
Interest income$10.9M$3.91M$1.78M$200K
Interest expense$0.00$0.00$0.00$10K
Depreciation and amortization$2.88M$1.15M$1.23M$1.34M
Ebitda-$-70.32M-$-53.6M-$-42.87M-$-63.4M
Operating income-$-71.68M-$-45.25M-$-35.85M-$-65.84M
Total other income/expenses, net-$-1.52M-$-9.51M-$-8.25M$1.09M
Income before tax-$-73.2M-$-54.76M-$-44.1M-$-64.75M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-73.2M-$-54.76M-$-44.1M-$-64.75M
Weighted average shares outstanding$40.5M$42.9M$42.9M$42.9M
Weighted average diluted shares outstanding$40.5M$42.9M$42.9M$42.9M
Balance sheet
2025202420232022
Cash and short-term investments$219.1M$103.6M$96.8M$27.7M
Net receivables$19.9M$12M$4.45M$0.00
Inventory$21.7M$13.3M$1.25M$0.00
Total current assets$267.9M$132.9M$103.6M$28.5M
Property, plant and equipment, net$15.2M$11.4M$6.2M$6.87M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$45.4M$0.00$100K$0.00
Total non-current assets$60.8M$16.7M$6.42M$7.06M
Total assets$328.7M$149.7M$110M$35.5M
Accounts payable$5M$2.85M$1.17M$430K
Short-term debt$1.94M$1.53M$1.22M$980K
Deferred revenue$1.56M$940K$90K$0.00
Total current liabilities$30.9M$21.2M$10.6M$8.87M
Long-term debt$5.37M$5.73M$3M$3.16M
Deferred revenue, non-current$3.3M$1.86M$260K$0.00
Total non-current liabilities$10.2M$52.5M$40.8M$196.7M
Capital lease obligations$7.3M$7.25M$3M$4.13M
Total liabilities$41.1M$73.6M$51.4M$205.6M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-369.94M-$-296.74M-$-229.66M-$-185.56M
Accumulated other comprehensive income (loss)$400K$70K$140K$0.00
Total equity$287.6M$76M$58.6M-$-170.03M
Total investments$233M$73.1M$70.3M$0.00
Total debt$7.3M$7.25M$4.22M$4.13M
Net debt-$-24.27M-$-23.18M-$-22.34M-$-23.54M
Cash flow statement
2025202420232022
Net income-$-73.2M-$-54.76M-$-44.1M-$-64.75M
Depreciation and amortization$2.88M$2.28M$2.09M$2.09M
Stock-based compensation$16.4M$6.38M$5.66M$6.1M
Change in working capital-$-8.99M-$-12.15M-$-5.3M-$-2.79M
Accounts receivable-$-5.16M-$-7.62M-$-4.49M$0.00
Inventory-$-9.88M-$-11.44M-$-1.19M$0.00
Accounts payable$2.1M$1.51M$720K-$-80K
Net cash provided by operating activities-$-50.92M-$-48.27M-$-32.45M-$-60.21M
Investments in property, plant and equipment-$-5.3M-$-3.4M-$-400K-$-770K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-162.81M-$-3.48M-$-69.69M-$-770K
Common stock issued$214.9M$100K$30K$390K
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$214.9M$55.6M$101M$56.8M
Net change in cash$1.14M$3.87M-$-1.11M-$-4.2M
Cash at end of period$31.7M$30.5M$26.7M$27.8M
Operating cash flow-$-50.92M-$-48.27M-$-32.45M-$-60.21M
Capital expenditure-$-5.3M-$-3.4M-$-400K-$-770K
Free cash flow-$-56.22M-$-51.67M-$-32.85M-$-60.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Beta Bionics, Inc.

        Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

        CEO
        Sean T. Saint
        Employees
        423
        Beta
        3.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Beta Bionics, Inc. (BBNX)?

        Beta Bionics, Inc. (BBNX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BBNX undervalued?

        BBNX trades at a price of $13.36 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.